Abstract
Little is known about the quality of polyclonal antibody responses in COVID-19 patients, and how it correlates with disease severity or patients’ prior exposure to other pathogens. The whole polyclonal antibody repertoire in a retrospective cohort of 538 individuals was mapped against SARS-CoV-2 spike (S) glycoprotein, the main target of antibody immune responses in SARS-CoV-2 infection. Bioinformatic predictions identified 15 major B cell epitopes for S of SARS-CoV-2. Several epitopes localised in RBD of S including those spanning the ACE2-binding site, the highly conserved cryptic epitope of the neutralizing antibody of SARS-CoV, and fusion/entry domains of HR1 and HR2 of S protein of SARS-CoV-2. Intriguingly, some of these epitopes have cross-reactivity to antigens of common pathogens, potentially affecting SARS-CoV-2 infection outcome. High level of anti-Spike SARS-CoV-2 seroreactivity in populations with no history of exposure to SARS-CoV-2 is of clinical relevance and could underpin better understanding of COVID-19 pathophysiology in different populations and provide a blueprint for design of effective vaccines and developing better strategies for antibody testing.
Competing Interest Statement
KP, MJ, AR, NP, HS and AP are employees of Protobios. KP and TT are founders of Protobios, KP serves as member of board of Protobios. AP and KP are inventors on a patent application (PCT Application No. US/14,079626) filed by Protobios, Inc. that covers the use of phage display method to manipulate and monitor humoral immunity. All other authors declare no competing interests.
Funding Statement
This study was supported by institutional research funding grants of Protobios (5.1-4/20/170, and PRG573) from the Estonian Research Council and H2020-MSCA-RISE-2016 (EU734791) from the European Union, Helsinki University Hospital grants, Mary and Georg C. Ehrnroth Foundation, Finnish Eye Foundation. KP, AA, and TT were partially supported by the institutional research grant IUT19-18 of TUT from the Estonian Research Council. This project has also received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement 760921 (PANBioRA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author (KP). The data are not publicly available due to containing information that could compromise research participant privacy/consent. Any materials that can be shared will be released via a material transfer agreement.
